Sponsor

Universitaetsklinikum Wuerzburg AöR

Germany Josef-Schneider-Strasse 2, Grombuehl, 97080 Wuerzburg, Germany

About the sponsor

Clinical research at Universitaetsklinikum Wuerzburg AöR includes solid tumour studies in adrenocortical carcinoma and ovarian cancer, with attention to postoperative disease control and treatment strategies for high-risk malignancies.

adjuvant treatment
recurrence-free survival
high-risk cancer

The sponsor’s oncology portfolio also reflects interest in treatment approaches for patients requiring additional systemic therapy after surgery.

About Specializations

Universitaetsklinikum Wuerzburg AöR runs clinical trials in conditions such as Plasma cell myeloma, Adrenocortical carcinoma, Cytokine release syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

4 clinical trials

Adrenocortical carcinoma

Recruiting

Study on Mitotane Alone or with Cisplatin and Etoposide for Patients with High-Risk Adrenocortical Carcinoma After Surgery

Registered drugNo placebo

Study on Mitotane Alone or with Cisplatin and Etoposide for Patients with High-Risk Adrenocortical Carcinoma After Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Cytokine release syndrome

Not yet recruiting

Study on Dasatinib for Preventing Side Effects in Patients with Relapsed or Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy

Registered drugNo placebo

Study on Dasatinib for Preventing Side Effects in Patients with Relapsed or Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dasatinib
Sponsor:Universitaetsklinikum Wuerzburg AöR

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on the Safety and Effectiveness of SLAMF7 CAR-T Cells for Patients with Multiple Myeloma

InvestigationalNo placebo

Study on the Safety and Effectiveness of SLAMF7 CAR-T Cells for Patients with Multiple Myeloma

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING AN ANTI-SLAMF7 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR
Sponsor:Universitaetsklinikum Wuerzburg AöR